38 results about "Glaucoma treatments" patented technology

A glaucoma treatment apparatus including an imaging device capable of imaging the anterior segment of the eye, a treatment laser, an algorithm programmed to determine a location and a cross sectional area of a treatment based on a customized anatomy of the anterior segment of the eye including the trabecular meshwork (TM), the Schlemm's Canal (SC) and collector channels (CCS), obtained from pre-operative images of the anterior segment of the eye, a pre-operative intraocular pressure (IOP) level and a target IOP reduction as an inputs, and a processor configured to actuate the apparatus to create an outflow channel with a cross-sectional area and location or multiple outflow channels with multiple cross-sectional areas and locations from the anterior chamber (AC) to the SC across the TM, as determined by the algorithm to achieve the target intraocular pressure (IOP) reduction. Also disclosed is a method of reducing intraocular pressure in an eye.

The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.

A simulated eye surgical model with a bubble management system that facilitates training of ophthalmic surgical procedures, such as laser-based glaucoma treatment. The simulated eye could also be used for marketing, startup procedures, go / no-go tests, etc. The eye model has a lower core, a corneal dome positioned above the lower core, and an anterior chamber under the corneal dome defining a floor. A bubble reservoir under the anterior chamber defined by the lower core has a capture tube opening to the anterior chamber. A bubble chamber open to the capture tube rises up above the capture tube lower end to an upper portion sealed off from the anterior chamber. The eye model may be rotated 360° about a horizontal axis to transfer bubbles from the anterior chamber to the bubble chamber. An alternative flow-through eye model provides active flushing of bubbles and particulate.

The invention relates to the technical field of biology. Specifically, the invention relates to an enhancer and a promoter for eye gene therapy, and a recombinant adeno-associated virus vector containing the enhancer and the promoter. The invention also relates to a pharmaceutical composition comprising the recombinant adeno-associated virus vector and its use in the treatment of glaucoma.

Methods for treating open-angle glaucoma include transitioning a patient from a twice-per-day or more treatment regimen to a once-per-day treatment regimen. The once-per-day treatment include administering a single dose of a pharmaceutical composition including timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof, once per day.

A system includes a first light source configured to emit visible light according to one or more first parameters and a second light source configured to emit treatment light for altering patient tissue. A surgical instrument includes a distal portion configured to insert within an eye of a patient and an optical fiber conducts light from the first and second light sources to a tip of the distal portion. One or more sensors are configured to detect a state of the tip of the distal portion relative to the patient tissue. A controller is coupled to the one or more sensors, the first light source, and the second light source. The controller is configured to select values for the one or more first parameters according to the state of the tip of the distal portion relative to the patient tissue.

Disclosed is a glaucoma device (10, 1010) comprising: an implant body (15, 1015) including an anterior portion (20, 1020), a distal portion (35, 1035), a plurality of arms (40, 1040) extending between the anterior portion (20, 1020) and the distal portion (35, 1035) to provide connection therebetween; and a fluid network extending from the anterior portion (20, 1020) along at least one of the arms (40, 1040) to the distal portion (35, 1035), the fluid network providing a plurality of outlet channels (90, 1090) for fluid exit therefrom; and a fluid inlet cannula (30, 1030) arranged on the anterior portion (20, 1020) of the implant body (15, 1015) and adapted for fluid connection with ocular tissue.

The invention relates to a drug sustained release system, in particular to lipid liquid crystal precursor eye drops as well as a preparation method and application thereof. The lipid liquid crystal precursor eye drops comprise a matrix material, a cosolvent and a raw material medicine, wherein the matrix material is an amphiphilic substance and an oil phase; the lipid liquid crystal precursor eye drops are prepared from the following components in percentage by weight: 0 to 35 percent of amphiphilic substance, 40 to 80 percent of oil phase, 15 to 20 percent of cosolvent and 0.001 to 5 percent of raw material medicine. According to the constructed drug-loaded lipid liquid crystal precursor eye drops, when the drug-loaded lipid liquid crystal precursor makes contact with water in tears, the drug-loaded lipid liquid crystal precursor can instantly become drug-loaded lipid liquid crystal gel, compared with common eye drops, the retention time of the drug-loaded lipid liquid crystal gel on the ocular surface is longer, the lipid liquid crystal has a phospholipid bilayer structure, and the drug-loaded lipid liquid crystal gel can be used for preparing the drug-loaded lipid liquid crystal precursor eye drops. Insoluble raw material medicines can be distributed in the lipid layer, so that the solubility of the raw material medicines is greatly improved, the raw material medicines can be slowly released by gelatinizing after meeting water, the administration frequency is reduced, the bioavailability and patient compliance are greatly improved, and the defects of the eye drops in treatment of glaucoma are overcome.

This invention relates to an ophthalmic method and apparatus for the treatment of glaucoma. It provides an apparatus and method of illuminating a microcatheter tip either by using green light for optimised visualisation, blue light to stimulate fluorescence or IR light in conjunction with a dye for angiography of vascular structures the light produced by an LED coupled to an optical fibre. Laser focussing optics is used and back scatter through the fibre is monitored. The backscatter information is used to automatically signify priming of the microcatheter with a fluid or signal changes in a fluid pump function or multiple fluid deliveries through a single microcatheter. Furthermore, the backscatter information offers the potential for automatic dispensation of fluids with or without operator intervention.

The utility model provides an ultrasonic fusion probe and glaucoma treatment equipment, and relates to the technical field of ophthalmology medical instruments, the ultrasonic fusion probe provided by the utility model comprises an ultrasonic imaging probe, a focused ultrasonic treatment probe and a rotating frame; the ultrasonic imaging probe is mounted on the rotating frame; and the focused ultrasonic treatment probe is detachably connected with the rotating frame. According to the ultrasonic fusion probe, synchronous action control of the ultrasonic imaging probe and the focused ultrasonic treatment probe can be achieved, the control difficulty is reduced, the focused ultrasonic treatment probe can be replaced according to needs, and the ultrasonic fusion probe is particularly suitable for accurate and quantitative treatment of glaucoma.

Systems and devices for applying radiation to a target area, for example for maintaining functioning drainage blebs or functioning drainage holes in the eye, e.g., to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The systems and devices of the present invention provide for the application of beta radiation to the target area, wherein the beta radiation can function to inhibit or reduce the inflammation and / or fibrogenesis that may occur after insertion of an implant into the eye or introduction of a hole for the purpose of draining aqueous humor to maintain a healthy intraocular pressure. By reducing inflammation and / or fibrogenesis, the implant, the hole, the blebs, or other related structures or tissues can remain functioning appropriately.

The invention relates to a method and device for treating eye diseases, and belongs to the field of medical treatment. In order to treat ocular hypertension and glaucoma, a device for reducing intraocular pressure is provided, the device comprising: a plate having a first end and a second end, the plate comprising opposing first and second surfaces wherein the first surface comprises a series of fluid channels, the series of fluid channels are configured in an open cross-network pattern extending from a first end of the plate to a second end of the plate, the width of the first end of the plate being narrower than the width of the second end of the plate to enable the first end of the plate to be inserted into the anterior chamber of the patient, and wherein the second surface comprises a plurality of open cells formed by the fluid channels; a first coating on the first surface, the first coating conforming to a topography of the series of fluid channels, and a second coating on the second surface. The devices described herein can be used to reduce intraocular pressure and treat glaucoma.

The present technology is directed to implantable medical devices for draining fluid from a first body region to a second body region. Some embodiments of the present technology provide adjustable devices that are selectively titratable to provide various levels of therapy. For example, the adjustable devices can have a drainage element with a lumen extending therethrough, a flow control element, and an actuation assembly. The actuation assembly can drive movement of the flow control element to change a dimension of and / or a flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of aqueous from an eye. In some embodiments, the actuation assembly and the flow control element together operate as a ratchet mechanism that can selectively move the flow control element between a plurality of positions and lock the device in a desired configuration until further actuation of the actuation assembly.

Methods, systems, and compositions for maintaining functional drainage blisters to reduce intraocular pressure (IOP) for treatment with glaucoma. The methods, systems, and compositions are characterized by minimally invasive glaucoma surgery (MIGS) implants or surgery in combination with application of beta rays to bubbles. The beta-rays may act to inhibit or reduce inflammation and / or fibrosis that typically occurs after insertion of the MIGS implant and results in blister failure. By reducing inflammation and / or fibrosis, the MIGS implants and vesicles may maintain appropriate function.

The invention belongs to the field of nano material synthesis, and particularly relates to a core-shell structure piezoelectric composite material loaded NO donor nano particle and application thereof.The core-shell structure piezoelectric composite material loaded NO donor nano particle comprises a core and a shell layer, the core is made of a layered bismuth-based piezoelectric material, the shell layer is made of a porous material, and the shell layer is made of a porous material. The nanoparticles with the core-shell structure are loaded with an NO donor drug. The nano-drug delivery system can be used as an eye drug delivery system based on ultrasonic mediation, and the first low-frequency ultrasonic response type nano-drug is provided for glaucoma treatment. By means of the innovative design of piezoelectric core / MOF drug loading / PDA sealing / PEG functionalization, the three problems that in glaucoma treatment, drug targeting is poor, release is uncontrollable, and frequent drug administration is needed are solved, and a safe, efficient and micro-intervention nanometer treatment new normal form is provided for irreversible blinding diseases.

An improved stimulus coil for use in wireless stimulation of biological tissue (e.g., nerves, muscle tissue, etc.) and, in one exemplary implementation, to glaucoma therapy based on the wireless administration of energy to the eye of a mammalian subject (e.g., human, rodent, etc.) to reduce an elevated intraocular pressure (IOP) involving the use of an improved stimulus coil. The improved stimulus coil may be implanted in the eye of a mammalian subject or positioned on the exterior of the eye, such as (by way of example) by being disposed within a contact lens worn by a mammalian subject.

The invention discloses an application of a miR-27a-3p inhibitor in preparation of a medicine for improving glaucoma. Glaucoma is a global main blinding neurodegenerative disease, retinal ganglion cell (RGC) apoptosis is a core pathological feature of the glaucoma, and existing intraocular pressure reduction treatment still cannot completely prevent neurodegenerative progress. Experiments prove that the miR-27a-3p inhibitor can be combined with 3 'UTR of PLK2 in a targeted mode, expression of the PLK2 is up-regulated, a PI3K / AKT signal channel is activated, and therefore RGC apoptosis is inhibited. A new glaucoma treatment strategy is provided, and the miR-27a-3p inhibitor can serve as an effective medicine to be used for improving glaucoma symptoms, protecting RGC and delaying disease progression and has good application prospects.

The present technology is directed to implantable medical devices for draining fluid from a first body region to a second body region. Some embodiments of the present technology provide adjustable devices that are selectively titratable to provide various levels of therapy. For example, the adjustable devices can have a drainage element with a lumen extending therethrough, a flow control element, and an actuation assembly. The actuation assembly can drive movement of the flow control element to change a dimension of and / or a flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of aqueous from an eye. In some embodiments, the actuation assembly and the flow control element together operate as a ratchet mechanism that can selectively move the flow control element between a plurality of positions and lock the device in a desired configuration until further actuation of the actuation assembly.

This invention discloses a glaucoma aqueous humor drainage tube implantation and injection device, relating to the field of glaucoma treatment technology. It includes a shell, with a baffle one and a baffle two fixedly connected to the inner wall of the shell. A cylinder is fixedly connected to the inner wall of baffle one and the top surface of baffle two. A drainage component is disposed inside the cylinder, and two sealing blocks are disposed below the cylinder. Body parts are fixedly connected to both sides of the shell, and adhesive patches are disposed below the two body parts. A driving component is disposed inside the shell. It also includes two sets of eye-expanding components, each disposed within one of the two body parts. The two sets of eye-expanding components allow the two adhesive patches to move synchronously with angular trajectory characteristics. Furthermore, it includes two sets of protective components, which allow the two sealing blocks to move in opposite directions. Through the cooperation of the above structures, this invention assists doctors in treating patients and helps patients recover better.

A glaucoma drainage device is provided having an elongated body for draining aqueous humor from the anterior chamber of the eye. At least one anchor or wire is configured to extend radially outward beyond the body to secure the body within the eye. The device, including the anchor or wire, is housed within the distal end of a needle inserter and deployed from there to implant the device within the eye. Deployment is performed by an extraocular or intraocular method. Once the device is loaded inside the needle inserter, the wire or anchor (or part thereof) is held in a compressed state. The wire or anchor (or part thereof) is configured to automatically expand from the compressed state to secure the device within the eye once deployed into the eye from the needle inserter. Related systems and methods for treating glaucoma are also described and claimed.

To provide adjustable glaucoma treatment devices, and associated systems and methods.SOLUTION: The present technology is directed to implantable medical devices for draining fluid from a first body region to a second body region. Some embodiments of the present technology provide adjustable devices that are selectively titratable to provide various levels of therapy. For example, the adjustable devices can have a drainage element with a lumen extending therethrough, a flow control element, and an actuation assembly. The actuation assembly can drive movement of the flow control element to change a dimension of and / or a flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of aqueous humor from an eye. In some embodiments, the actuation assembly and the flow control element together operate as a ratchet mechanism that can selectively move the flow control element between a plurality of positions and lock the device in a desired configuration until further actuation of the actuation assembly.SELECTED DRAWING: Figure 2

A simulated eye surgical model with a bubble management system that facilitates training of ophthalmic surgical procedures, such as laser-based glaucoma treatment. The simulated eye could also be used for marketing, startup procedures, go / no-go tests, etc. The eye model has a lower core, a corneal dome positioned above the lower core, and an anterior chamber under the corneal dome defining a floor. A bubble reservoir under the anterior chamber defined by the lower core has a capture tube opening to the anterior chamber. A bubble chamber open to the capture tube rises up above the capture tube lower end to an upper portion sealed off from the anterior chamber. The eye model may be rotated 360° about a horizontal axis to transfer bubbles from the anterior chamber to the bubble chamber. An alternative flow-through eye model provides active flushing of bubbles and particulate.

An improved stimulus coil for use in wireless stimulation of biological tissue (e.g., nerves, muscle tissue, etc.) and, in one exemplary implementation, to glaucoma therapy based on the wireless administration of energy to the eye of a mammalian subject (e.g., human, rodent, etc.) to reduce an elevated intraocular pressure (IOP) involving the use of an improved stimulus coil. The improved stimulus coil may be implanted in the eye of a mammalian subject or positioned on the exterior of the eye, such as (by way of example) by being disposed within a contact lens worn by a mammalian subject.

The application provides a kind of nano preparation with antioxidant function and the use for treating glaucoma, the preparation is composed of oil phase and water phase.Oil phase is lecithin, medium-chain triglyceride, fat-soluble antioxidant, glaucoma treatment drug, water phase is water-soluble antioxidant or deionized water.The nano delivery system described in the application is by loading glaucoma treatment drug in the nano preparation containing antioxidant, can improve local drug concentration, prolong drug retention time, at the same time, through antioxidant scavenging excess active oxygen, reduce inflammatory response, reduce eye cell apoptosis, so as to achieve good therapeutic effect.The nano preparation described in the application can be nano emulsion, liposome, micelle or lipid nanoparticle and other drug delivery systems.The nano preparation can deliver therapeutic drugs while scavenging ROS, reducing eye inflammation and reducing cell apoptosis to achieve more efficient therapeutic effect, with the characteristics of double effect, easy to produce and prepare, wide application range, etc.

The application discloses sgRNA targeting carbonic anhydrase 2 and application thereof. The sgRNA targeting carbonic anhydrase 2 comprises sgRNA as shown in SEQ ID NO. 1 and sgRNA as shown in SEQ ID NO. 2. The application develops sgRNA for double-site knockout of ciliary body Car2 based on CRISPR-Cas9 and AAV technology, realizes efficient Car2 targeting, has high knockout efficiency, effectively inhibits aqueous humor production, has obvious effect of reducing intraocular pressure and long maintenance time, significantly reduces retinal ganglion cell apoptosis, can be used for glaucoma treatment, and has wide application prospect.

A system for treating glaucoma is disclosed that includes a modular tube diverter implant having a flexible plate and a separable fluid drainage tube that are separately inserted and connected after insertion. The system includes a tube inserter featuring a delivery cannula having a needle tip-like distal end and a plunger having a pop-up rod configured to pierce the sclera and deliver the tube into the anterior chamber. A plate inserter, also including a cannula and a plunger, is configured to deploy the flexible plate in a compact form through the same small conjunctival incision, where the flexible plate is deployed to fit over the sclera. The connecting mechanism can easily connect the plate and the pipe through the notch. The system is specially designed for minimally invasive surgery, and therefore efficient deployment of the two components is achieved through the small-diameter cannula, and tissue damage and recovery time are reduced.

The present disclosure relates to a drug for preventing and / or treating glaucoma. Specifically, provided in the present disclosure is the use of an adenosine A2A receptor antagonist in the treatment and prevention of glaucoma. The treatment and prevention include, but are not limited to, inhibiting aqueous humor production in non-pigmented epithelial cells of the ciliary body, reducing elevated intraocular pressure caused by the obstruction of aqueous humor outflow due to fibrosis and thickening of the trabecular meshwork, improving the fluidity of aqueous humor in the eye, inhibiting pathological changes in the trabecular meshwork, and achieving a protective effect on retinal cells. Additionally, the drug of the present disclosure may also help to reduce the problem of drug tolerance in the treatment of glaucoma, can lower intraocular pressure in glaucoma patients and provide a protective effect on optic nerves, and provides a more effective strategy for long-term treatment.

A simulated eye surgical model with a bubble management system that facilitates training of ophthalmic surgical procedures, such as laser-based glaucoma treatment. The simulated eye could also be used for marketing, startup procedures, go / no-go tests, etc. The eye model has a lower core, a corneal dome positioned above the lower core, and an anterior chamber under the corneal dome defining a floor. A bubble reservoir under the anterior chamber defined by the lower core has a capture tube opening to the anterior chamber. A bubble chamber open to the capture tube rises up above the capture tube lower end to an upper portion sealed off from the anterior chamber. The eye model may be rotated 360° about a horizontal axis to transfer bubbles from the anterior chamber to the bubble chamber. An alternative flow-through eye model provides active flushing of bubbles and particulate.

Described herein are biomimetic microfluidic devices. In some embodiments, the devices may be a glaucoma eye organ-on-a-chip microfluidic device. Also described herein is a method of culturing and monitoring one or more cell types and a method of screening one or more anti-glaucoma therapeutic agents using the disclosed biomimetic microfluidic devices. In some embodiments, the disclosed devices may be used to investigate trabecular meshwork cell function and ocular outflow as they relate to glaucoma pathology.